Basic Stalevo Information

• INN (International Nonproprietary Name): Levodopa, Carbidopa, Entacapone.
• Brand Names Available In United Kingdom: Stalevo supplied as brown, oval film-coated tablets, prescription only.
• ATC Code: N04BA03.
• Forms & Dosages: Film-coated tablets in strengths that combine levodopa, carbidopa and 200 mg entacapone per tablet.
• Manufacturers In United Kingdom: Novartis / Orion (distributed by national subsidiaries).
• Registration Status In United Kingdom: Authorised for prescription use; marketed in the EU since 2005 and approved in other major markets.
• OTC / Rx Classification: Prescription Only Medicine (Rx).
• Available Tablet Strengths:
  • Stalevo 50: 50 mg levodopa / 12.5 mg carbidopa / 200 mg entacapone.
  • Stalevo 75: 75 mg levodopa / 18.75 mg carbidopa / 200 mg entacapone.
  • Stalevo 100: 100 mg levodopa / 25 mg carbidopa / 200 mg entacapone.
  • Stalevo 125: 125 mg levodopa / 31.25 mg carbidopa / 200 mg entacapone.
  • Stalevo 150: 150 mg levodopa / 37.5 mg carbidopa / 200 mg entacapone.
  • Stalevo 200: 200 mg levodopa / 50 mg carbidopa / 200 mg entacapone.
• Storage Advice: Store below 30°C and protect from moisture and light.
• Indication Summary: Treatment of Parkinson’s disease in adults with motor fluctuations despite standard levodopa/DDCI therapy.

Latest Research Highlights

What Does Recent UK And EU Research Say About Stalevo?

Recent literature from 2022–2025 has focussed on optimising levodopa regimens, sequencing of COMT inhibitors and quality-of-life outcomes in motor fluctuations.

Several multicentre randomised controlled trials and real-world registries compared fixed triple therapy (levodopa/carbidopa/entacapone) against levodopa/DDCI with or without separate entacapone.

The consistent findings were reduced daily "off" time and improved UPDRS motor scores with single-tablet triple therapy in many datasets.

Reported safety signals have remained in line with expectations: dyskinesia, orthostatic hypotension and urine discolouration were the common adverse events noted.

Regulatory Notes: Stalevo has EMA marketing authorisation since 2005 and MHRA national authorisation in the UK.

• Key Takeaway: Trials and registries point to reduced "off" time and improved motor scores with fixed triple therapy versus levodopa/DDCI alone.
• Key Takeaway: Safety profile unchanged from known levodopa and entacapone effects, with dyskinesia and orthostatic symptoms as main concerns.
• Key Takeaway: Data on exact minute reductions in "off" time and discontinuation percentages are not specified in the public summary here.

Clinical Effectiveness In The UK

How Does Stalevo Perform In NHS Practice?

NHS audits and clinic-level experience show Stalevo is commonly used for adults with Parkinson’s who experience wearing-off despite levodopa/DDCI therapy.

Switching to the fixed triple-combination often improves daily "on" time and reduces requirement for rescue medication in many patients.

Some patients report faster improvement in morning akinesia after conversion to a Stalevo regimen.

MHRA Yellow Card monitoring reflects trial safety signals, particularly an increase in dyskinesia and orthostatic symptoms that may require dose adjustment.

• Practical Note: NHS cost-effectiveness analyses typically favour single-tablet combinations where adherence or pill burden is a barrier.
• Practical Note: Initiation usually occurs in neurology or movement-disorder clinics with continuation via GP repeat prescribing under shared-care arrangements.

Indications And Expanded Uses

Who Is Stalevo For And When Is It Used Off-Label?

Per product information, Stalevo is authorised for treatment of Parkinson’s disease in adults with motor fluctuations ('wearing off') despite levodopa/DDCI therapy.

In NHS practice the primary aim is to reduce off time and simplify dosing for patients with adherence difficulties.

Off-label uses are limited and usually managed by specialist neurologists; examples include complex dyskinesia strategies and some palliative scenarios.

Stalevo is not indicated in children under 18 years of age.

• Approved Indication: Motor fluctuations in adults despite levodopa/DDCI therapy.
• Common Off-Label Scenarios: Specialist-managed dyskinesia adjustments; palliative symptom control when appropriate.
• Switch Decision Flowchart (Short):
  1. Patient Has Wearing-Off Despite Levodopa/DDCI?
  2. If Yes, Consider Adding COMT Inhibitor Or Switching To Fixed Triple Tablet.
  3. Does Patient Have Adherence Or Pill-Burden Issues?
  4. If Yes, Stalevo May Be Preferred As A Direct Switch From Co-careldopa Plus Separate Entacapone.

Composition And Brand Landscape

What Is In Each Tablet And Which Brands Exist In The Market?

Stalevo is a fixed triple combination of levodopa, carbidopa and entacapone with each tablet containing 200 mg entacapone.

Marketed strengths vary by levodopa/carbidopa content, from 50/12.5/200 up to 200/50/200.

In the UK Stalevo is supplied as brown, oval film-coated tablets for prescription-only use and is typically distributed by Novartis or Orion.

Stalevo 50

50 mg levodopa / 12.5 mg carbidopa / 200 mg entacapone.

Stalevo 75

75 mg levodopa / 18.75 mg carbidopa / 200 mg entacapone.

Stalevo 100

100 mg levodopa / 25 mg carbidopa / 200 mg entacapone.

Stalevo 125

125 mg levodopa / 31.25 mg carbidopa / 200 mg entacapone.

Stalevo 150

150 mg levodopa / 37.5 mg carbidopa / 200 mg entacapone.

Stalevo 200

200 mg levodopa / 50 mg carbidopa / 200 mg entacapone.

Competitors include levodopa/carbidopa products such as Sinemet and levodopa/benserazide products such as Madopar, and separate entacapone formulations like Comtan.

Contraindications And Special Precautions

Who Should Not Take Stalevo And What Warnings Matter?

Absolute contraindications include known hypersensitivity to any component, narrow-angle glaucoma, severe liver disease and pheochromocytoma.

Relative contraindications include severe cardiovascular disease, severe renal impairment, a history of psychosis and concurrent use with non-selective MAO inhibitors.

Use in pregnancy and breastfeeding should be avoided unless the expected benefit justifies the potential risk, and Stalevo is not licensed for paediatric use.

Practical UK Advice: Counsel patients about driving if they experience dizziness or sudden sleepiness, and warn that alcohol can potentiate orthostatic effects.

Dosage Guidelines

How Is Stalevo Initiated And Adjusted?

Initiation is performed by matching the patient’s current levodopa/DDCI dose to the nearest Stalevo strength and then titrating clinically.

Maintenance therapy is commonly one tablet per dose given three to seven times daily as required for symptom control.

The maximum recommended limit is 200 mg levodopa per dose and a total levodopa ceiling of 2,000 mg per day.

Special-population notes: Not indicated for children, use lower starting doses in the elderly, exercise caution in renal impairment and avoid or reduce dose in hepatic impairment due to increased entacapone exposure.

1. Confirm Total Levodopa/DDCI Daily Dose.
2. Choose Closest Stalevo Tablet Strength.
3. Start At That Strength And Monitor Symptoms And Side Effects.
4. Adjust Frequency (3–7 Times Daily) To Achieve Symptom Control.
5. Do Not Exceed 200 mg Levodopa Per Dose Or 2,000 mg Per Day.

Interactions Overview

Which Medicines And Foods Interact With Stalevo?

Key drug interactions include non-selective MAO inhibitors, which are contraindicated, and dopamine antagonists such as some antipsychotics that reduce levodopa effect.

Entacapone increases levodopa exposure and hepatic impairment increases entacapone levels, so monitoring is essential.

High-protein meals may impair levodopa absorption and alcohol can worsen orthostatic hypotension.

• Non-Selective MAO Inhibitors → Contraindicated.
• Dopamine Antagonists (Antipsychotics) → May Reduce Effect; Review Necessity.
• Antihypertensives → Monitor For Orthostatic Hypotension.
• Selective Serotonergic Antidepressants → Use With Caution; Monitor For Interaction Effects.

Pharmacists should check antidepressants, antihypertensives and neuroleptics at each supply because Yellow Card reports include interaction-related AEs such as falls and worsening dyskinesia.

Cultural Perceptions And Patient Habits

What Do Patients In The UK Say About Stalevo?

Patient communities frequently raise pill burden, timing complexity and fear of dyskinesia as common concerns.

Many patients favour single-tablet solutions like Stalevo for easier adherence and convenience when travelling.

Patients often expect detailed counselling from pharmacists about timing, benefits and potential side effects.

Typical NHS access points for urgent queries include NHS 111 and GP helplines, while Parkinson’s UK and forum communities remain important peer resources.

• What Patients Say: "Fewer tablets each day makes life simpler."
• What Patients Say: "I was told my dyskinesia might increase but my off periods reduced."
• Practical Tip: Use NHS patient portals to manage repeat prescriptions and shared-care notes.

Availability And Pricing Patterns

How Can Patients Get Stalevo In The United Kingdom?

Stalevo is prescription-only in the UK and is authorised and distributed by Novartis / Orion.

It is stocked by major pharmacy chains and is available through NHS-approved online pharmacies and electronic prescription services.

In our online pharmacy, stalevo is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Prescription costs differ across the UK nations: prescriptions are free in Scotland, Wales and Northern Ireland, whereas England operates a standard charge unless the patient is exempt.

Single-tablet combinations can be more expensive privately than separate generic components, but may be cost-effective when adherence and pill burden are considered.

Comparable Medicines And Preferences

When Is Stalevo Preferred Over Alternatives?

Alternatives include Sinemet (levodopa/carbidopa), Madopar (levodopa/benserazide) and separate entacapone (Comtan).

Pros of Stalevo include simplified dosing and consistent entacapone delivery of 200 mg per tablet.

Cons include reduced flexibility for fine-tuning levodopa and carbidopa separately and potentially higher private cost.

• Pros Checklist: Reduced pill burden, consistent entacapone dosing, easier adherence for some patients.
• Cons Checklist: Less granular titration of individual components, potential cost considerations.

Decision Matrix (Short): Patients with adherence problems or frequent wearing-off often suit Stalevo, whereas patients needing fine-tuned levodopa adjustments may prefer separate components.

Frequently Asked Questions

• Can I Switch From My Current Levodopa To Stalevo? Specialists usually match total levodopa/DDCI dose to the nearest Stalevo strength and titrate; discuss with your neurologist or GP.
• Will Stalevo Make Me Dyskinetic? Increased levodopa exposure can raise dyskinesia risk; clinicians balance off-time reduction with dyskinesia and may alter the dose.
• Is It Free On The NHS? Prescription charges depend on which UK nation you live in; Scotland, Wales and Northern Ireland provide free prescriptions while England applies charges unless you are exempt.
• What Should I Watch For At Home? Report dizziness, urine discolouration or sudden sleepiness to your pharmacist or GP and consider using the MHRA Yellow Card to report suspected adverse reactions.

Guidelines For Proper Use — UK Pharmacist Counselling Style

What Should Pharmacists Tell Patients When Dispensing Stalevo?

Confirm the exact Stalevo strength and the prescribed dosing schedule before supply.

Advise patients to take doses consistently relative to meals and to avoid high-protein meals at dosing times where possible.

Warn about common effects such as urine discolouration and orthostatic dizziness and advise patients not to drive if these occur.

Missed-dose rule: Take as soon as remembered but do not double the next dose; then resume the regular schedule.

• Counselling Checklist: Confirm strength, discuss timing and food effects, warn about urine colour, review driving and machinery use.
• Storage Advice: Store below 30°C in the original packaging.
• Signposting: Refer to NHS patient portals, Parkinson’s UK resources and the MHRA Yellow Card for reporting.

Delivery Across United Kingdom